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Background: Human papillomavirus (HPV) is associated to the pathogenesis of various cancers, such as oropharyngeal
squamous cell carcinoma, which has a high incidence in Puerto Rican men. Despite the burden of oral cancer in Puerto
Rico, little is known about the epidemiology of oral HPV infection, particularly in high-risk men. Therefore, this study is
aimed at determining the prevalence of oral HPV infection, the genotype distribution and correlates associated with
oral HPV infection in men of at least 16 years of age attending a sexually transmitted infection (STI) clinic in Puerto Rico.
Methods: A cross-sectional study consisting of 205 men was conducted. Participants provided a 30-second oral rinse
and gargle with mouthwash. Following DNA extraction, HPV genotyping was performed in all samples using
Innogenetics Line Price Assay (INNO-LiPA). A questionnaire was administered, which included a demographic,
behavioral and a clinical assessment. Descriptive statistics and bivariate analysis were used to characterize the
study sample. Variables that achieved statistical significance in the bivariate analysis (p < 0.05) were assessed in
multivariate logistic regression models.
Results: The mean age of the study sample was 38.5 ± 14.2 years. Oral HPV prevalence among men was 20.0%
(95.0%CI = 14.8%-26.1%) and of HPV type 16 was 2.4% (95.0%CI = 0.8%-5.6%). Oral HPV prevalence significantly
increased over increasing age categories (p-trend = 0.001). Multivariate analysis showed that oral HPV was
independently associated with number of sexual partners (adjusted OR = 1.02; 95%CI = 1.01-1.03) and lifetime use
of cigarettes (adjusted OR = 3.00; 95%CI = 0.98-9.16).
Conclusions: Oral HPV among the sampled men in the STI clinic was high, regardless of the HIV status or sexual
behavior. Interventions in STI clinics should include screening for HPV in the oral cavity for the early detection
and reduction of long-term consequences of oral HPV infection, such as oropharyngeal cancer.
Keywords: Oral HPV infection, Epidemiology, High-risk men, STI/STD clinic, Puerto RicoBackground
Human papillomavirus (HPV) infection is considered
the most common sexually transmitted infection (STI)
[1]. About 6 million people are diagnosed each year and
approximately 9.0-13.0% of the world population (630
million people) is already infected with the disease [2].
HPV plays a role in the pathogenesis of Head and Neck
Squamous Cell Carcinomas (HNSCCs) and Oropharyn-
geal Squamous Cell Carcinomas (OPSCCs) [3,4]. The* Correspondence: vivian.colon@upr.edu
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article, unless otherwise stated.incidence and mortality rates of HNSCCs have increased
in several countries over the last three decades [5-9].
These group of cancers are clinically characterized by
the presence of oncogenic high-risk (HR) HPV, predom-
inantly type 16, that has been detected approximately in
95.0% of positive tumors [10,11]. In head and neck can-
cers, studies have shown that the prevalence of HPV
DNA varies by cancer site and geography [12]. HPV
DNA has been found in 35–50% in developed countries
in contrast with the rest of the oral cavity, where HPV
DNA is found in 5–15% of the cases [12]. HNSCCs have
broad varying rates of incidence and mortality worldwide,
with higher rates in European countries and Southeast
Asia [13]. According to data from nine Surveillance,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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from 1973 to 2004, in the United States (US), the inci-
dence of HNSCC increased particularly in young and mid-
dle aged individuals (<60 years) and men [14]. This cancer
type is currently the eighth most common cancer among
men in the US [15,16].
Some studies have found several risk factors that increase
the risk of HPV in the oral cavity. Tobacco smoking and
alcohol consumption are the main risk factors for HNSCC
[15,16]. Although the incidence of HPV-unrelated OPSCC
associated with tobacco and alcohol use has declined over
recent decades, OPSCC related to HPV has significantly
increased [4]. These increases in the prevalence of HPV in
the oral cavity may be the result of changes in sexual be-
haviors [10]. Oral HPV prevalence is more than 8-fold
higher among sexually experienced individuals as com-
pared to sexually inexperienced individuals and increases
significantly with number of sexual partners [17]. This
prevalence has been as high as 20.0% among individuals
who have reported more than 20 lifetime sexual partners
during their lifetime [17]. Additionally, men with multiple
lifetime male sex partners (MSM) are 2 to 4 times more
likely to be HPV 6 or 11, seropositive and 3 to 11 times
more likely to be seropositive to HPV 16 or 18 [18]. Also,
high rates of oral HPV infection have been found in HIV
(Human immunodeficiency virus) seropositive individuals
[1,10,19,20]. A study has also shown the HPV prevalence
to be higher among current smokers (20.7%) and heavy
alcohol drinkers (12.3%) [17].
Studies concerning the epidemiology of oral HPV in-
fection in men are limited since much of the research
focuses on factors associated with cervical cancer in
women [21,22]. However, as the causes for the excess
risk of HPV-related cancers in the US remains unclear
[17], it is important to determine epidemiology the for
this group. For example, although a substantial percent-
age of oropharyngeal cancer is attributed to alcohol
(7.0-19.0%) and tobacco exposure (25.0%) [23], in the
US about one quarter of the oral cancer cases in men and
approximately half of those in women in Puerto Rico are
not attributed to these exposures [24]. These findings for
Puerto Rico are consistent with US data [25] and highlight
the need to further understand the epidemiology of HPV
infection in the oral cavity, as well as its relationship with
oral cancers and anogenital infection.
Furthermore, the limited epidemiological and behav-
ioral research on oropharyngeal HPV infection in men,
including the high-risk groups, may delay the develop-
ment of effective interventions to reduce the burden of
oral HPV infection. For Puerto Rico in particular, men
have had a higher incidence and mortality of oropharyn-
geal cancer as compared with Hispanics in the US [26].
According to the Puerto Rico Central Cancer Registry,
from 2005–2009, this cancer type was considered thefourth most common cancer among men in Puerto Rico
[27]. Puerto Rican men also have had a higher mortality
risk of the disease as compared with non-Hispanic
whites and non-Hispanic blacks in the US [26].
Therefore, given the burden of oropharyngeal cancer
in Puerto Rico, the aim of this study was to (1) deter-
minate the prevalence of HPV infection in the oral re-
gion and (2) to identify socio-demographic, behavioral
and clinical risk factors associated with oral HPV infec-
tion in men attending a STI clinic in San Juan, Puerto
Rico. STI clinics can be an ideal venue for targeting oral
HPV infection epidemiology in high risk groups of men,
such as men who have sex with men (MSM), HIV-
positive men, and men with STIs other than genital
warts. Therefore, data collected from this venue may
offer the opportunity to reach these vulnerable and
underserved populations more efficiently than general-
population studies.
Methods
Study design and research procedures
This study consisted of a cross-sectional study with men
attending a publicly funded STI clinic in San Juan,
Puerto Rico. A convenience sample was drawn from 205
men from within the clinic’s waiting room, coupled with
subsequent screening to confirm eligibility (at least 16
years of age) and informed consent. Study participation
was voluntary and written informed consent, including
Health Insurance Portability and Accountability Act
(HIPAA) forms, notifying about the nature of the study,
general purpose, the types of research and clinical proce-
dures involved, were provided. All study design, written
consent and data collection procedures were approved by
the University of Puerto Rico-Medical Sciences Campus
(UPR MSC) Institutional Review Board (IRB).
Behavioral interview
The behavioral interview was completed in approxi-
mately 25 minutes by a trained interviewer. Domains
included demographic characteristics (e.g. age, place of
birth, current residence, employment, and educational
attainment), detailed assessment of sexual risk (e.g. includ-
ing age of onset, current sexual partners and practices),
and assessment of alcohol, cigarette and drug use- (e.g.
types, frequency, and mode of administration of illicit/ille-
gal drugs such as: marihuana, cocaine, heroin, and crack).
Additionally, the assessment included questions about
health history (self-reported STI’s and HIV status).
Variables of interest
A person was considered oral HPV positive if resulted
positive to any of the 27 types tested, whereas all others
were considered negative. Behavioral characteristics in-
cluded patterns of smoking tobacco, smoking marihuana,
Colon-López et al. BMC Oral Health 2014, 14:7 Page 3 of 10
http://www.biomedcentral.com/1472-6831/14/7and drinking. Lifetime and recent cigarette and marihuana
smoking, as well as lifetime alcohol use were measured.
Lifetime smoking was defined as having smoked at least
once during the lifetime. Current smoking was defined as
smoking at least one cigarette per day for the past 12
months. Years smoking was defined as the number of
years spent smoking regularly. Lifetime smoking of mari-
huana was measured as “ever smoked marihuana”, which
referred to having smoked marihuana at least once during
lifetime. “Ever smoked marihuana in the past 12 months”
was defined as having smoked marihuana at least once
during the past 12 months. Lifetime alcohol use was
measured as “ever having an alcoholic beverage”, which
referred to drinking at least once during lifetime.
The self-reported sexual characteristics analyzed within
the sample dealt with sexual behavior, including lifetime
and recent oral sex. Men who had sex with men (MSM)
was a self-reported measure from the question: “Regarding
your lifetime sexual partners, how many of them have
been men?” Those participants that answered “1 or more
men”, were categorized as “men who had sex with men”
(MSM) in their lifetime. Those that answered zero (0)
were categorized as non-MSM. Lifetime oral sex was de-
fined as having had oral sex at least once during lifetime.
Recent oral sex was defined as having had oral sex at least
once during the past 12 months.
Oral HPV specimen collection
All of the specimen collection and HPV polymerase
chain reaction (PCR) procedures used in this study have
been extensively tested and refined, and used in multiple
previously published studies [28,29]. After completion of
the behavioral interview, participants underwent collec-
tion of biological specimens by trained physicians at the
study site. An oral mouthwash sample was collected to
obtain DNA for HPV genotyping. Oral rinse samples
were collected as previously described in the National
Health and Nutrition Examination Survey (NHANES)
[30]. Briefly, each participant vigorously swished and gar-
gled 10 ml of Scope mouthwash for 30 seconds. This was
followed by depositing the Scope and saliva generated
from the mouthwash into a specimen collection cup.
DNA extraction/ inno-LiPA HPV genotyping testing
DNA was extracted using the DNA purification from
buccal cells protocol from Gentra PureGene Kit (Qiagen,
Valencia, CA) and following the manufacturer’s instruc-
tions. The concentration of each DNA was quantified
and qualified spectrophotometrically using a Nanodrop
HPV genotyping was determined in all study samples
using the INNO-LiPA HPV Genotyping Extra assay
(Innogenetics, Belgium) and following the manufac-
turer’s instructions. The INNO-LiPA HPV assay is a
PCR-based hybridization assay that includes a cocktailof biotinylated consensus primers (small primer frag-
ment (SPF) 10) to amplify a portion of the L1 open
reading frame (ORF) of 13 established HR HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66), 5
known or putative HR types (26, 53, 68, 73, and 82), 7
LR HPV types (6, 11, 40, 43, 44, 54, and 70), additional
non-differentiated HPV types, and types with un-
defined risk (74 and 69/71). After DNA extraction, all
specimens were subjected to PCR amplification (40 cycles)
using the Inno-LiPA HPV Genotyping Extra Amp. The
PCR product was then denatured, and a 10-μl aliquot was
hybridized onto nitrocellulose strips where the HPV type-
specific oligonucleotides were already bound. After 60 min
at 49°C, the PCR product bound to a specific probe was
detected by an alkaline phosphatase-streptavidin conjugate
and colorimetric detection. Results were visually inter-
preted by experienced laboratory personnel using the refer-
ence guide provided. Some types are defined by a single
positive probe on the genotyping strip (i.e., HPV6, -11, and
−16), but others are interpreted as a combination of two to
four probes (i.e., HPV18, -33, and −58). While the manu-
facturer provides interpretation of type detection, including
“possible” types, only those that were detected unequivo-
cally were included in the analysis.
Statistical analysis
Frequency distributions and descriptive statistics were
first used to characterize the study sample in terms of
demographics, behavioral and HIV status. Overall preva-
lence of oral HPV infection was estimated, along with
95.0% binomial confidence interval (CI). Frequency dis-
tributions were used to describe the DNA HPV-types
detected in the oral cavity. Chi-square tests, Fisher’s
exact tests, and independent t-tests were used to evalu-
ate differences in demographic, behavioral, and HIV sta-
tus. Statistical significance was set at p-value <0.05.
Variables that resulted significantly associated with oral
HPV seroprevalence in the bivariate analyses were later
evaluated for possible collinearity. A Pearson correl-
ation of 0.5 or greater and a p-value for the two-tailed
significance test <0.05 was considered as a significant
correlation.
Factors significantly associated with oral HPV infec-
tion were included in a logistic regression analysis. Dif-
ferent binary logistic regression models were developed
in order to investigate the relationship between the se-
lected risk factors and the occurrence of any type of oral
HPV infection. Associations with oral HPV prevalence
were reported as crude and adjusted Odds Ratios (ORs),
along with 95%CIs and significance assessed through the
Wald test p-value < 0.05. Trend tests were conducted
across age categories. Goodness of fit for all models was
assessed using the log likelihood estimates. In order to
choose the best model, the log likelihood estimates were
Colon-López et al. BMC Oral Health 2014, 14:7 Page 4 of 10
http://www.biomedcentral.com/1472-6831/14/7compared by subtracting each model’s log likelihood
from the base model’s log likelihood. First-order interac-
tions between the significant factors of the chosen model
were also evaluated in the logistic regression analysis.
Statistical analyses were performed using the statistical
package SPSS (Version 21.0, Chicago, IL), while 95% con-
fidence intervals (CI) for prevalence estimations were per-
formed using the Binomial CI Calculator from STATA
Statistical Software (Release 11, College Station, TX).
Results
Participant characteristics
The demographic and behavioral characteristics of the
205 participating men are shown in Table 1. The mean
age of the study sample was 38.5 years (standard deviation
[SD] = 14.2). The majority (65.2%) had a high school edu-
cation or less and was employed (53.9%). Also, public
health insurance was predominant among the sample
(58.9%); although 18.3% reported not having any type of
medical insurance.
The mean years for smoking was 23.9 years (SD =14.3).
More than half of the interviewed men had smoked at
least once in their lifetime (73.5%), reported to be current
smokers (65.8%), and had at least one alcoholic beverage
in their lifetime (95.1%). Though the majority had smoked
marihuana at least once in their lifetime (62.3%), they
reported not having smoked marihuana in the past 12
months (55.2%).
Half of the sample reported having HIV (50.2%). The
mean years of living with HIV was 11.5 years (SD =
8.4 years). Oral HPV infection was observed among 22.3%
of the HIV positive men and 17.8% among HIV negative
men. Additionally, approximately a third (29.5%) of the
participants indicated having had sex with another man
(MSM). The vast majority of the MSM’s interviewed in
this sample had reported oral sex at least once in their life-
time (91.2%) and at least once in the past 12 months
(91.7%). These results were also consistent with those who
reported being heterosexual, in which a vast majority
(91.9%) reported having had oral sex at least once in their
lifetime and 76.0% having had oral sex at least once in the
past 12 months.
Oral HPV prevalence
The prevalence estimates for oral HPV infection by the 27
individual genotypes analyzed among the 205 participating
men aged 16–81 years are shown in Table 2. The prevalence
of oral HPV infection among men was 20.0% (95% CI =
14.8%, 26.1%). The prevalence of high-risk HPV infection
was 10.7% (95% CI = 6.8%, 15.8%) and for low-risk HPV was
7.3% (95% CI = 4.2%, 11.8%). The most prevalent high-risk
subtype was HPV-52 (2.9%), while the most prevalent low-
risk subtype was HPV-6 (3.9%). HPV types 18, 26, 33, 45,
53, 59, 79/71, and 82 were not detected in this sample.Factors associated with oral HPV infection in bivariate
analysis
Table 3 shows the results for the associations between
demographic, behavioral, and clinical characteristics with
HPV status. Oral HPV prevalence was significantly
associated with age, lifetime smoking, years smoking,
lifetime marihuana use, and lifetime number of sexual
partners. However, bivariate correlation analyses dem-
onstrated that having smoked at least once during life-
time, having smoked marihuana at least once during
lifetime, and years smoking were significantly correlated
(p-value <0.05). Upon this result, we only included
“having smoked at least once during lifetime” for subse-
quent analyses.
Factors associated with oral HPV infection in logistic
regression analyses
Results for the univariate and multivariate logistic re-
gression models evaluating the association of demo-
graphic and behavioral variables with the likelihood of
HPV infection are demonstrated in Table 4. In the un-
adjusted logistic regression model, factors independently
associated with increased prevalence odds of HPV infec-
tion included: age, lifetime smoking and lifetime number
of sexual partners. The prevalence of any type of oral
HPV significantly increased over increasing age categor-
ies (p-trend = 0.001). Men who had smoked at least
once in their lifetime were three times more likely to test
positive for any HPV type infection (OR = 3.10; 95% CI =
1.15, 8.36) as compared with those who had never smoked
in their lifetime. Also, per every unit increase in lifetime
sexual partners, the prevalence of oral HPV infection
increased by 2%.
In the complete multivariate model (model 3), lifetime
smoking and lifetime sex partners remained independ-
ently associated with detection of any type of oral HPV.
Odds of detecting any type of oral HPV infection
remained three-fold higher among men who had
smoked at least once in their lifetime compared to those
who had never smoked (OR = 3.00; 95% CI = 0.98, 9.16),
after adjusting for differences in age and number of life-
time sexual partners. This association was marginally
significant. Odds of detecting any type of oral HPV in-
fection remained significantly higher among men with
increased number of lifetime sex partners (OR = 1.02;
95% CI = 1.01, 1.03), after adjusting for differences in age
and lifetime smoking. No significant first-order interac-
tions were observed between age, lifetime smoking, and
lifetime sex partners.
Discussion
The prevalence of any type of oral HPV infection among
men participating in this study was 20.0% (95% CI =
14.8%-26.1%). After multivariate regression analysis, any
Table 1 Demographic and risk related characteristics
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Table 1 Demographic and risk related characteristics
among 205 HIV+/HIV- men attending an STI clinic in
Puerto Rico (Continued)










MSW who had oral sex at least once in their lifetime
No 13 8.1
Yes 147 91.9
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among men with a higher mean number of lifetime sex-
ual partners. A series of studies on oral HPV prevalence
Table 2 Oral HPV prevalence by individual genotypes
among 205 HIV+/HIV-men attending an STI clinic in
Puerto Rico
HPV type n (N=205) % (95% CI)
Any HPV type 41 20 (14.8-26.1)




















Multiple† 11 5.4 (2.7-9.4)
†Those that have two or more HPV types.
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MSM or HIV +men) from which results of oral HPV
prevalence have varied. For example, in Melbourne,
Australia the prevalence of oral HPV among MSM’s at-
tending a sexual health center was 13.0% [35]. This preva-
lence resulted slightly lower than that reported in similar
study settings among MSM’s in Amsterdam (24.4%) [34]
and among HIV-infected MSM’s in Italy (21.3%) [36]. Al-
though comparisons with other studies are not possible
due to differences in the sample, the prevalence of oral
HPV among MSM in our study was 19.3%.
In our study, although a higher prevalence of oral
HPV infection was observed among HIV positive men
(22.3% in HIV-positive vs. 17.8% in HIV-negative), this
association was not significant. Also, neither sexual be-
havior nor oral sexual practices were significantly associ-
ated with any type of oral HPV detection. This may be
explained by the selection of a high sexual risk group of
men attending a public STI clinic, which lacked enough
heterogeneity with regards to some risk factors.
Prevalence of oral HPV significantly increased within in-
creasing age categories. The peak prevalence was foundamong men aged 55–81 years of age (34.5%). This increas-
ing trend could be explained by an increased oral HPV in-
cidence with age [17], persistent and/or reactivated oral
HPV infections [31] due to loss of immunity as age in-
creases [17,37], and/or increased persistence among older
individuals [17,38]. However, it is important to clarify that
although a trend was found between oral HPV and age,
the association between these variables did not remain sta-
tistically significant after adjusting for lifetime sex partners
and lifetime smoking in the multivariate logistic regression
model.
The multivariate logistic regression model for any type
of oral HPV infection demonstrated an independent sig-
nificant association with lifetime number of sex partners
and a marginal independent association with lifetime
smoking, after adjusting for differences in age categories.
Increased odds of any type of oral HPV infection among
men with increased number of sex partners is supported
by the literature [17], indicating that oral HPV infection
is higher among sexually experienced individuals than by
nonsexual contact. The association with lifetime smok-
ing, though marginal, may confirm the biological plausi-
bility associated with oral HPV infection [33]. Cigarette
smoking inhibits a variety of immune responses in the
oral cavity [39], which may allow for increased HPV per-
sistence [33]. The oral epithelial abrasion due to the dir-
ect exposure to the carcinogens in tobacco may also
represent the pathway for increased HPV detection
among smokers [35].
The findings of this study need to be interpreted with
caution because of its inherent limitations. We acknow-
ledge that perhaps the sample size of 205 men was not
sufficient for this type of study. Though this number can
be considered fair in other types of research, we found it
to be insufficient for this type of setting, especially when
creating categories for certain outcome variables and in
analyses for associations with clinical characteristics.
Oral HPV infection was measured once, so it was not
possible to differentiate between newly acquired, persist-
ent, or reactivated infections [31]. Site of infection, such
as the oral cavity or the oropharynx, was also not pos-
sible to differentiate, due to the oral rinse sampling tech-
nique used [31]. We recognize additional limitations in
the way some of the behavioral and clinical variables
were measured. This study relied upon self-reported
data for HIV status, which could lead to misclassification
and residual confounding. Among HIV positive men,
CD4 T-cell count, viral load and highly active antiretro-
viral therapy (HAART) use, was not available. Also, the
lack of frequency measures for alcohol, tobacco, and ma-
rihuana use limited the interpretation of the results. Per-
haps measuring recent use, within the past 6 or 12
months, and measuring the quantity of use for these be-
havioral variables could have provided a more detailed
Table 3 Oral HPV prevalence and risk factors among 205








16-24 88.6 (39) 11.4 (5) 0.002
25-34 97.6 (40) 2.4 (1)
35-44 73.2 (30) 26.8 (11)
45-54 71.7 (33) 28.3 (13)
55+ 65.5 (19) 34.5 (10)
Level of education
< High School 75.9 (41) 24.1 (13) 0.154
High School 75.9 (60) 24.1 (19)
> High School 87.3 (62) 12.7 (9)
Employed
No 79.1 (34) 20.9 (9) 0.134
Yes 82.7 (91) 17.3 (19)
Type of Health Insurance
None 83.8 (31) 16.2 (6) 0.751
Public 78.2 (93) 21.8 (26)
Private 80.4 (37) 19.6 (9)
Behavioral
Ever smoked
No 90.7 (49) 9.3 (5) 0.020
Yes 76.0 (114) 24.0 (36)
Current smoker
No 73.2 (30) 26.8 (11) 0.514
Yes 78.5 (62) 21.5 (17)
Years Smoking 75.0 (87) 25.0 (29)
Mean (SD) 22.3 (14.5) 28.7 (12.5) 0.038
Ever had an alcoholic beverage
No 90.0 (9) 10.0 (1) 0.367
Yes 79.4 (154) 20.6 (40)
Ever smoked marihuana
No 87.0 (67) 13.0 (10) 0.048
Yes 75.6 (96) 24.4 (31)
Ever smoked marihuana in the past 12 months
No 69.6 (48) 30.4 (21) 0.105
Yes 82.1 (46) 17.9 (10)
Sexual Activity
Lifetime number of sexual
partners
79.4 (158) 20.6 (41) 0.005
Mean (SD) 20.2 (28.9) 65.9 (98.2)
MSM
No 80.1 (109) 19.9 (27) 0.930
Table 3 Oral HPV prevalence and risk factors among 205
HIV+/HIV- men attending an STI clinic in Puerto Rico
(Continued)
Yes 80.7 (46) 19.3 (11)
MSM who had oral sex at least once in their lifetime
No 80.0 (4) 20.0 (1) 0.673
Yes 80.8 (42) 19.2 (10)
MSM who had oral sex at least once in the past 12 months
No 33.3 (1) 66.7 (2) 0.066
Yes 87.9 (29) 12.1 (4)
MSW
No 86.7 (26) 13.3 (4) 0.525
Yes 81.9 (131) 18.1 (29)
MSW who had oral sex at least once in their lifetime
No 92.3 (12) 7.7 (1) 0.276
Yes 81.0 (119) 19.0 (28)
MSW who had oral sex at least once in the past 12 months
No 79.3 (23) 20.7 (6) 0.688
Yes 82.6 (76) 17.4 (16)
Clinical
HIV
No 82.2 (83) 17.8 (18) 0.422
Yes 77.7 (80) 22.3 (23)
Years living with HIV 79.2 (80) 29.8 (21) 0.644
Mean (SD) 11.3 (8.8) 12.2 (6.9)
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variables and oral HPV in men. Categorizing these vari-
ables into more detailed recent use measurements could
have increased validity and power.
Also, due to the small sample size among MSM’s, op-
portunities to determine recent MSM behavior (i.e. last
3 months) and conduct multivariable analyses were not
possible. Other limitations include the lack of data re-
garding the use of condoms and other variables which
could help us understand sexual partnering and prevent-
ive practices among MSM. Furthermore, we were unable
to examine MSM sociocultural contexts, like violence,
stigma, homophobia, social networks, and the construc-
tion of gender identities. Future studies need to explore
these social determinants when attempting to under-
stand the sexual behavior and HPV/HIV-related risks to
which the participants of this study setting are exposed
in Puerto Rico.
Since the study was conducted in a high risk STI public
clinic, our findings are unlikely to be generalizable to pop-
ulations at lower sexual risk. However, data collected from
a highly selective population, such as a public STI clinic,
may also offer an opportunity to reach targeted high-risk
groups more efficiently than general population-based
Table 4 Logistic regression results for associations with HPV among 205 men attending an STI clinic in Puerto Rico
Variable Unadjusted OR (95% CI) p-value Model 1 Adjusted OR (95% CI) p-value Model 2 Adjusted OR (95% CI) p-value Model 3 Adjusted OR (95% CI) p-value
Age at recruitment
16-24 1.00 1.00 0.021* 1.00 0.059* 1.00 0.074*
25-34 0.20 (0.02, 1.75) 0.144 0.15 (0.02, 1.40) 0.097 0.18 (0.02,1.62) 0.126 0.13 (0.01,1.22) 0.075
35-44 2.87 (0.90, 9.12) 0.076 2.28 (0.70, 7.43) 0.172 2.39 (0.70,8.18) 0.164 1.86 (0.54, 6.46) 0.328
45-54 3.07 (0.99, 9.52) 0.052 2.68 (0.85, 8.47) 0.093 2.77 (8.53, 8.96) 0.090 2.28 (0.69, 7.51) 0.174
55+ 4.11 (1.23, 13.70) 0.022 3.68 (1.08,12.57) 0.037 2.54 (0.70,9.26) 0.157 2.15 (0.58, 7.98) 0.254
P trend 0.001
Log Likelihood 180.39
Lifetime sex partners 1.02 (1.01,1.03) <0.001 1.02 (1.01, 1.03) 0.002 1.02 (1.01,1.03) 0.002
Log Likelihood 180.47 161.22
Lifetime smoking
No 1.00 1.00 1.00
Yes 3.10 (1.15,8.36) 0.026 3.20 (1.14, 8.95) 0.027 3.00 (0.98,9.16) 0.054
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http://www.biomedcentral.com/1472-6831/14/7studies. As described in other studies [40,41], participants
attending publicly funded STI clinics are likely to be
young, uninsured and poor. Therefore, this scenario has
helped target oral HPV infection analyses among a vulner-
able population.
To our knowledge, this is the first study currently exam-
ining the epidemiology of oral HPV infection among men
attending a public STI clinic in Puerto Rico. Since previ-
ous studies have reported that men in Puerto Rico have a
higher incidence and mortality of oropharyngeal cancer
as compared to Hispanics in the US [26], future studies
should further elucidate if potential interactions between
alcohol use, tobacco use, and HPV infection may explain
the higher burden of oral cancer in this population. Also,
preventive efforts in this area are warranted. However,
primary preventive interventions in this high sexual risk
setting can be too late and ineffective. Since our study
demonstrated a high oral HPV prevalence, capacity build-
ing and training on malignancies in the oral cavity among
the medical staff are recommended. This type of interven-
tion in a high risk setting can be appropriate to reduce
complications and comorbidities.
Conclusions
This study reports on the prevalence of and risk factors
associated with oral HPV infection in a sample of men
attending a public STI clinic in Puerto Rico. Oral HPV
prevalence was high, regardless of the HIV status and
sexual behavior of men attending the STI clinic of inter-
est for this study. Lifetime smoking and lifetime sex
partners were independently associated with any type of
oral HPV infection in the multivariate logistic regression
model. Future interventions in this type of setting should
focus on screening for HPV in the oral cavity as a way
of early detection and reduction of malignant changes,
HPV-related cancers, and other comorbidities.
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